Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:CBM

Cambrex (CBM) Stock Price, News & Analysis

Cambrex logo

About Cambrex Stock (NYSE:CBM)

Advanced Chart

Key Stats

Today's Range
$59.99
$59.99
50-Day Range
$59.99
$59.99
52-Week Range
$33.80
$60.29
Volume
N/A
Average Volume
218,726 shs
Market Capitalization
$2.02 billion
P/E Ratio
21.66
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter.

CBM Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
China CBM Group Co Ltd 08270
See More Headlines

CBM Stock Analysis - Frequently Asked Questions

Cambrex Co. (NYSE:CBM) issued its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.05. The business's revenue for the quarter was up 13.0% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cambrex investors own include Bristol-Myers Squibb (BMY), Illumina (ILMN), AbbVie (ABBV), Meta Platforms (META), CVS Health (CVS), Gilead Sciences (GILD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/02/2018
Today
5/29/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:CBM
Fax
N/A
Employees
1,732
Year Founded
N/A

Profitability

Trailing P/E Ratio
21.66
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$92.41 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$532.09 million
Cash Flow
$3.91 per share
Price / Cash Flow
15.36
Book Value
$19.48 per share
Price / Book
3.08

Miscellaneous

Free Float
N/A
Market Cap
$2.02 billion
Optionable
Optionable
Beta
2.14
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NYSE:CBM) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners